SeaSpine Reports 1Q19 Revenue of $36.2MM, +9% vs. 1Q18

by Mike Evers on May 06, 2019

SeaSpine reported 1Q19 revenue of USD $36.2MM, +9% vs. 1Q18.

Increased 2019 guidance by $2MM (1.5%) on the low end, bringing updated guidance range to $154MM to $156MM (+7.5 to 9% vs. 2018)
Spine revenue growth driven by new products, particularly the Shoreline and Mariner systems along with NanoMetalene products
Orthobiologics...

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

	1Q19	1Q18	$ Chg	% Chg
Spine	$17.1	$15.2	$2.0	13.0%
Orthobiologics	$19.0	$18.0	$1.0	5.6%
Total	$36.2	$33.2	$3.0	9.0%

Geographic Region	1Q19	1Q18	$ Chg	% Chg
US	$32.0	$29.5	$2.4	8.3%
Ex-US	$4.2	$3.6	$0.5	14.5%
Total	$36.2	$33.2	$3.0	9.0%

1Q19	Amount ($MM)	% of Sales
Sales	$36.2
Cost of Sales	-$13.6	37.6%
Other	-$0.74	2.0%
R & D	-$3.5	9.7%
Selling and Admin	-$27.3	75.5%
Net Earnings	-$9.0	-24.9%

	1Q19	1Q18	$ Chg	% Chg
Spine	$17.1	$15.2	$2.0	13.0%
Orthobiologics	$19.0	$18.0	$1.0	5.6%
Total	$36.2	$33.2	$3.0	9.0%

Geographic Region	1Q19	1Q18	$ Chg	% Chg
US	$32.0	$29.5	$2.4	8.3%
Ex-US	$4.2	$3.6	$0.5	14.5%
Total	$36.2	$33.2	$3.0	9.0%

SeaSpine Reports 1Q19 Revenue of $36.2MM, +9% vs. 1Q18

Orthopedics’ Top Tier to Expand in 2024

Miach Orthopaedics Raises $20 Million in Series B Extension

10 Orthopedic Companies Close New Funding Rounds in 1Q24

Carlsmed Raises Series C to Support aprevo

U.S. Market Key to Unlocking Orthofix’s Trauma Business

Get the ORTHOWORLD Newsletter!

Contact Us